Powered by

Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer

Jun 18, 2019 - GlobeNewswire
Board and Executive Moves

REDWOOD CITY, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the hiring of Ronald A. Krasnow as General Counsel and Chief Compliance Officer.  In this role, Mr. Krasnow will be responsible for all legal needs of the company including intellectual property portfolio development and supporting the company's commercial, clinical...